Finanzas de Palvella Therapeutics Inc (PVLA)PVLAPalvella Therapeutics Inc

Evaluating the bottom line, Palvella Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -46.63%, provide a clear picture of how effectively PVLA converts its operational activities into shareholder value.

In the context of the broader market, PVLA competes directly with industry leaders such as TRVI and VIR. With a market capitalization of $1.80B, it holds a significant position in the sector. When comparing efficiency, PVLA's gross margin of N/A stands against TRVI's N/A and VIR's 100.00%. Such benchmarking helps identify whether Palvella Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Palvella has reported increasing net losses, with Q2 2026 showing a net income loss of -$21.87 million. The current ratio is strong at 21.18, indicating good short-term financial health, but the company has a negative P/E ratio of -32.49, reflecting ongoing losses.